EP0855910A4 - Conjugates useful in the treatment of benign prostatic hyperplasia - Google Patents

Conjugates useful in the treatment of benign prostatic hyperplasia

Info

Publication number
EP0855910A4
EP0855910A4 EP96936504A EP96936504A EP0855910A4 EP 0855910 A4 EP0855910 A4 EP 0855910A4 EP 96936504 A EP96936504 A EP 96936504A EP 96936504 A EP96936504 A EP 96936504A EP 0855910 A4 EP0855910 A4 EP 0855910A4
Authority
EP
European Patent Office
Prior art keywords
treatment
benign prostatic
prostatic hyperplasia
conjugates useful
conjugates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP96936504A
Other languages
German (de)
French (fr)
Other versions
EP0855910A1 (en
Inventor
Deborah Defeo-Jones
Raymond E Jones
Allen I Oliff
Edward M Scolnick
Victor M Garsky
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9602903.8A external-priority patent/GB9602903D0/en
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of EP0855910A1 publication Critical patent/EP0855910A1/en
Publication of EP0855910A4 publication Critical patent/EP0855910A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
EP96936504A 1995-10-18 1996-10-15 Conjugates useful in the treatment of benign prostatic hyperplasia Withdrawn EP0855910A4 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US566495P 1995-10-18 1995-10-18
US5664P 1995-10-18
GB9602903 1996-02-13
GBGB9602903.8A GB9602903D0 (en) 1996-02-13 1996-02-13 Conjugates useful in the treatment of benign prostatic hyperplasia
PCT/US1996/016490 WO1997014416A1 (en) 1995-10-18 1996-10-15 Conjugates useful in the treatment of benign prostatic hyperplasia

Publications (2)

Publication Number Publication Date
EP0855910A1 EP0855910A1 (en) 1998-08-05
EP0855910A4 true EP0855910A4 (en) 2000-07-05

Family

ID=26308676

Family Applications (1)

Application Number Title Priority Date Filing Date
EP96936504A Withdrawn EP0855910A4 (en) 1995-10-18 1996-10-15 Conjugates useful in the treatment of benign prostatic hyperplasia

Country Status (4)

Country Link
EP (1) EP0855910A4 (en)
JP (1) JP2000506494A (en)
AU (1) AU708475B2 (en)
WO (1) WO1997014416A1 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001501601A (en) * 1996-09-12 2001-02-06 メルク エンド カンパニー インコーポレーテッド Conjugates useful in treating prostate cancer
HRP970566A2 (en) * 1996-10-30 1998-08-31 Jones Deborah Defeo Conjugates useful in the treatment of prostate canser
US5948750A (en) * 1996-10-30 1999-09-07 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
PL197006B1 (en) * 1997-12-02 2008-02-29 Merck & Co Inc Conjugates useful in treating prostatic carcinoma
US6174858B1 (en) 1998-11-17 2001-01-16 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
US6613879B1 (en) * 1999-05-14 2003-09-02 Boehringer Ingelheim Pharma Kg FAP-activated anti-tumour compounds
WO2000069472A2 (en) 1999-05-14 2000-11-23 Boehringer Ingelheim Pharmaceuticals, Inc. Enzyme-activated anti-tumor prodrug compounds
EP1228089A2 (en) * 1999-10-27 2002-08-07 Merck & Co., Inc. Salt form of a conjugate useful in the treatment of prostate cancer
JP2003526683A (en) 2000-03-15 2003-09-09 ブリストル−マイヤーズ スクイブ ファーマ カンパニー Peptidase-cleavable targeted antineoplastic drugs and their therapeutic use
GB0027552D0 (en) * 2000-11-10 2000-12-27 Boehringer Ingelheim Pharma Anti-tumor compounds
GB0027551D0 (en) * 2000-11-10 2000-12-27 Boehringer Ingelheim Pharma Anti-tumor compounds
WO2003094972A2 (en) * 2002-05-10 2003-11-20 Boehringer Ingelheim Pharma Gmbh & Co Kg Fap-activated anti-tumor prodrugs
CA3203072A1 (en) 2020-12-22 2022-06-30 Andrea CASAZZA Compounds comprising a tetrapeptidic moiety
WO2022167664A1 (en) 2021-02-07 2022-08-11 Cobiores Nv Compounds comprising a tetrapeptidic moiety

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0247792A2 (en) * 1986-05-27 1987-12-02 Eli Lilly And Company Immunoglobulin conjugates
EP0282057A2 (en) * 1987-03-11 1988-09-14 The Board Of Regents Of The University Of Michigan Chemo-radio-immuno-conjugates
WO1992010212A1 (en) * 1990-12-05 1992-06-25 Farmitalia Carlo Erba Srl Anthracycline-conjugates

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5391723A (en) * 1989-05-31 1995-02-21 Neorx Corporation Oligonucleotide conjugates
US5137877B1 (en) * 1990-05-14 1996-01-30 Bristol Myers Squibb Co Bifunctional linking compounds conjugates and methods for their production
SE9002480D0 (en) * 1990-07-23 1990-07-23 Hans Lilja ASSAY OF FREE AND COMPLEXED PROSTATE-SPECIFIC ANTIGEN
US5502037A (en) * 1993-07-09 1996-03-26 Neuromed Technologies, Inc. Pro-cytotoxic drug conjugates for anticancer therapy
US6143864A (en) * 1994-06-28 2000-11-07 Merck & Co., Inc. Peptides

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0247792A2 (en) * 1986-05-27 1987-12-02 Eli Lilly And Company Immunoglobulin conjugates
EP0282057A2 (en) * 1987-03-11 1988-09-14 The Board Of Regents Of The University Of Michigan Chemo-radio-immuno-conjugates
WO1992010212A1 (en) * 1990-12-05 1992-06-25 Farmitalia Carlo Erba Srl Anthracycline-conjugates

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
LILJA ET AL.: "Molecular cloning of epididymal and seminal vesicular transcripts encoding a semenogelin-related protein", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 89, May 1992 (1992-05-01), pages 4559 - 4563, XP002137094 *
See also references of WO9714416A1 *
TESSMER ET AL.: "Biological activity of prostate-specific antigen isolated...", ELECTROPHORESIS, vol. 16, no. 5, May 1995 (1995-05-01), pages 793 - 799, XP000901881 *

Also Published As

Publication number Publication date
AU708475B2 (en) 1999-08-05
EP0855910A1 (en) 1998-08-05
WO1997014416A1 (en) 1997-04-24
JP2000506494A (en) 2000-05-30
AU7432196A (en) 1997-05-07

Similar Documents

Publication Publication Date Title
EP0926955A4 (en) Conjugates useful in the treatment of prostate cancer
NO993396L (en) Quinoline and quinoline compounds useful in therapy, especially in the treatment of benign prostatic hyperplasia
HUP0000651A3 (en) Conjugates useful in the treatment of prostate cancer
AU3011299A (en) Combination therapy for the treatment of benign prostatic hyperplasia
EP0855910A4 (en) Conjugates useful in the treatment of benign prostatic hyperplasia
AU1657097A (en) Use of alpha1-adrenoreceptor antagonists in the prevention and treatment of benign prostatic hyperplasia
PL340768A1 (en) Conjugates useful in treating prostatic carcinoma
IL132836A0 (en) Arylsubstituted piperazines useful in the treatment of benign prostatic hyperplasia
ZA982819B (en) Treatment or prophylaxis of prostatic cancer and benign prostatic hyperplasia with selective estrogn receptor modulators.
HK1030776A1 (en) Substituted pyridino arylpiperazines useful in the treatment of benign prostatic hyperplasia
ZA9810974B (en) Conjugates useful in the treatment of prostate cancer
AU9128998A (en) Composition and method for the treatment of benign prostatic hyperplasia and prostatitis
EP0733365A3 (en) Use of benzoquinolin-3-ones for the treatment and prevention of prostatic cancer
AU6570998A (en) Prostate specific antigen from benign prostatic hyperplasia and its use in diagnosis
GB9602903D0 (en) Conjugates useful in the treatment of benign prostatic hyperplasia
EP0748627A3 (en) Melatonin agonists for use in the treatment of benign prostatic hyperplasia
ZA991319B (en) Novel phthalimido arylpiperazines useful in the treatment of benign prostatic hyperplasia.
EP1140906A4 (en) Imidazolones and their use in treating benign prostatic hyperplasia and other disorders
AU2002300904A1 (en) Arylsubstituted piperazines useful in the treatment of benign prostatic hyperplasia
ZA979655B (en) Conjugates useful in the treatment of prostate cancer.
AU2003204320A1 (en) Heterocycles useful in the treatment of benign prostatic hyperplasia and intermediates thereof
GB9624170D0 (en) Conjugates useful in the treatment of prostate cancer
GB9626309D0 (en) Conjugates useful in the treatment of prostate cancer
SI0942754T1 (en) Conjugates useful in the treatment of prostate cancer
GB9810895D0 (en) Combination therapy for the treatment of benign prostatic hyperplasia

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19980518

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

RIC1 Information provided on ipc code assigned before grant

Free format text: 7A 61K 31/40 A, 7A 61K 31/44 B, 7A 61K 31/70 B, 7A 61K 38/02 B, 7A 61K 38/07 B, 7A 61K 38/08 B, 7A 61K 38/10 B, 7A 61K 38/14 B, 7A 61K 47/48 B

A4 Supplementary search report drawn up and despatched

Effective date: 20000522

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

17Q First examination report despatched

Effective date: 20031204

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20040415